Ascendis Pharma A/S
ASND
154 hedge funds and large institutions have $7.13B invested in Ascendis Pharma A/S in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 22 closing their positions.
209% more call options, than puts
Call options by funds: $55.3M | Put options by funds: $17.9M
59% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 41
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
31% more capital invested
Capital invested by funds: $5.45B → $7.13B (+$1.68B)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
5% more funds holding
Funds holding: 147 → 154 (+7)
0.29% less ownership
Funds ownership: 100.83% → 100.54% (-0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$202M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$76.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$31.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$31.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$237M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$55.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$32.5M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$28.2M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$25.6M |
ASND Hedge Fund Activity: Q2 2020 in Review
154 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2020, worth a combined $7.13B — up 31% from $5.45B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ASND positions and 22 closed out — a net gain of 7 holders — while 65 added to existing stakes and 41 trimmed.
The largest buyer was Artisan Partners, adding an estimated $202M. The largest seller was OrbiMed, cutting an estimated $237M.
- 154 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2020, up from 147 in Q1 2020.
- Funds reported $7.13B of Ascendis Pharma A/S stock for Q2 2020, up 31% quarter-over-quarter.
- 29 funds opened new Ascendis Pharma A/S positions in Q2 2020 and 22 closed out, a net change of +7 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2020 was Artisan Partners, an estimated $202M added.
- The largest Ascendis Pharma A/S seller in Q2 2020 was OrbiMed, an estimated $237M sold.
Based on aggregated 13F filings for Q2 2020.